Unit:
Διατμηματικό / Διϊδρυτικό ΠΜΣ Μοριακή ΙατρικήLibrary of the School of Health Sciences
Author:
Μπακαλγιάννη Αγγελική
Supervisors info:
Καθηγητής Βιολογίας κ. Νικόλαος Π. Ανάγνου
Original Title:
Μελέτη της επίδρασης γενετικά τροποποιημένων μεσεγχυματικών βλαστικών κυττάρων στη θεραπεία του καρκίνου της ουροδόχου κύστεως
Translated title:
Study of the effect of genetically modified mesenchymal stem cells in the treatment of bladder cancer
Summary:
The objective of the present study is to evaluate the use of genetically
modified AF-MSCs in the targeted cell therapy of bladder cancer. Initially, to
this end, the in vitro anticancer properties of various anticancer molecules
were evaluated, in order to select the most effective anticancer agent for the
genetic modification of AF-MSCs. More specifically, the effect of the cytokines
TRAIL, IL-21, IL-24 and the PEDF factor on the proliferation rate of the
metastatic bladder cancer cell line T24M was studied. The in vitro
antiangiogenic properties of the PEDF factor were investigated as well.
According to the above studies, the molecule TRAIL was chosen as the most
effective anti-cancer agent and a lentiviral expression system of this protein
was constructed and used for the genetic modification of AF-MSCs (TRAIL
AF-MSCs). Afterwards, the in vitro antitumor effect of transduced TRAIL AF-MSCs
on the cell line T24M was documented. Subsequently, the in vivo activity of
TRAIL AF-MSCs was studied in an animal model of bladder cancer. For the
establishment of tumors, T24M cells were subcutaneously administered in
NOD/SCID mice. The TRAIL AF-MSCs were administered intravenously into the
animal models and were found to inhibit the growth of tumor size.
In conclusion, the results of this study demonstrated the antitumor activity of
TRAIL AF-MSCs in metastatic cancer cell line T24M in vitro as well as in vivo
in an animal model of bladder cancer. AF-MSCs can be successfully utilized for
the delivery of tumor suppressor agents in the tumor area in order to achieve
effective treatment of cancer.
Keywords:
Amniotic fluid, Mesenchymal stem cells, TRAIL, Bladder cancer, Cell therapy
Number of references:
195
File:
File access is restricted.
document.pdf
2 MB
File access is restricted.
